Full identifier: http://www.w3.org/2000/01/rdf-schema#SENTENCE
Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
---|---|---|---|---|---|---|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:59:11.220Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:59:09.305Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:59:07.616Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:59:05.405Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:59:03.853Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:59:01.706Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:59:00.024Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:58:58.096Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:58:56.051Z
|
||
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
SENTENCE
|
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
|
Eva Zegelaar
|
2021-12-16T19:58:54.680Z
|
||